Drug · CHEMBL435

HYDROCHLOROTHIAZIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. HYDROCHLOROTHIAZIDE. Drugs and targets, record CHEMBL435. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL435

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: HYDROCHLOROTHIAZIDE; ChEMBL
ChEMBL ID: CHEMBL435; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Apo-hydro, Esidrex, Esidrix, Hydro-d, Hydrochlorothiazide component of accuretic, Hydrochlorothiazide component of aldactazide, Hydrochlorothiazide component of aldoril, Hydrochlorothiazide component of amturnide, Hydrochlorothiazide component of apresazide, Hydrochlorothiazide component of apresoline-esidrix, Hydrochlorothiazide component of avalide, Hydrochlorothiazide component of benicar hct, Hydrochlorothiazide component of cam-ap-es, Hydrochlorothiazide component of diovan hct, Hydrochlorothiazide component of dutoprol, Hydrochlorothiazide component of dyazide, Hydrochlorothiazide component of esimil, Hydrochlorothiazide component of exforge hct, Hydrochlorothiazide component of h.r.-50, Hydrochlorothiazide component of hydra-zide, Hydrochlorothiazide component of hydralazine hydrochloride--reserpine, Hydrochlorothiazide component of hydrap-es, Hydrochlorothiazide component of hydro-reserp, Hydrochlorothiazide component of hydro-ride, Hydrochlorothiazide component of hydropres, Hydrochlorothiazide component of hydroserpine plus (r-h-h), Hydrochlorothiazide component of hyzaar, Hydrochlorothiazide component of ibersartan/ zentiva, Hydrochlorothiazide component of ifirmacombi, Hydrochlorothiazide component of irbesartan/ teva, Hydrochlorothiazide component of irbesartan/-bms, Hydrochlorothiazide component of kervezide, Hydrochlorothiazide component of kinzalkomb, Hydrochlorothiazide component of lopressor hct, Hydrochlorothiazide component of lotensin hct, Hydrochlorothiazide component of maxzide, Hydrochlorothiazide component of micardis hct, Hydrochlorothiazide component of micardisplus, Hydrochlorothiazide component of moduretic, Hydrochlorothiazide component of monopril hct, Hydrochlorothiazide component of normozide, Hydrochlorothiazide component of oreticyl forte, Hydrochlorothiazide component of polycap, Hydrochlorothiazide component of prinzide, Hydrochlorothiazide component of pritorplus, Hydrochlorothiazide component of quinaretic, Hydrochlorothiazide component of rasitrio, Hydrochlorothiazide component of riprazo, Hydrochlorothiazide component of ser-a-gen, Hydrochlorothiazide component of ser-ap-es, Hydrochlorothiazide component of serpasil-esidrix, Hydrochlorothiazide component of sprimeo-hct, Hydrochlorothiazide component of tekturna hct, Hydrochlorothiazide component of teveten hct, Hydrochlorothiazide component of tolucombi, Hydrochlorothiazide component of tribenzor, Hydrochlorothiazide component of unipres, Hydrochlorothiazide component of uniretic, Hydrochlorothiazide component of vaseretic, Hydrochlorothiazide component of viskazide, Hydrochlorothiazide component of zestoretic, Hydrochlorothiazide component of ziac, Hydrochlorothiazide intensol, Hydrodiuril, Hydrosaluric, Microzide, Oretic, Ziac, Zide; ChEMBL
Other names: Apresazide, Carozide, Chlorosulthiadil, Copalia-hct, Dafiro-hct, Dihydrochlorurite, Exforge-hct, Hidroclorotiazida, Hidrotiazida, Hydrochlorothiaizide, Hydrochlorothiazidum, Hydrochlorthiazide, Idrotiazide, Imprida-hct, Lotensin hct, Megadiuril, NSC-53477, Newtolide, Pantemon, Rasilez-hct, SU-5879, Servithiazid, Unipres, Vetidrex; ChEMBL
DrugBank: DB00999; DrugBank
InChIKey: JZUFKLXOESDKRF-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 16 of its 42 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
SLC12A3	Solute carrier family 12 member 3	Thiazide-sensitive sodium-chloride cotransporter inhibitor	INHIBITOR	https://conductscience.org/library/genes/6559

Source ChEMBL

Diseases42

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	415	165	https://conductscience.org/library/drugs?q=MONDO_0005044
essential hypertension	Approval	EMA Human Drugs	39	38	https://conductscience.org/library/drugs?q=MONDO_0001134
type 2 diabetes mellitus	Phase 2	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0005148
cardiovascular disorder	Approval	ATC	7	5	https://conductscience.org/library/drugs?q=MONDO_0004995
heart failure	Approval	DailyMed	5	4	https://conductscience.org/library/drugs?q=MONDO_0005252
chronic kidney disease	Approval	DailyMed	101	3	https://conductscience.org/library/drugs?q=MONDO_0005300
diabetes mellitus	Approval	DailyMed	4	3	https://conductscience.org/library/drugs?q=MONDO_0005015
Isolated systolic hypertension	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=HP_0500106
Hypernatremia	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0003228
albuminuria	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0004285

1 to 10 of 42Source Open Targets

See all 42 diseases

Trials387

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00923091	Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension	Phase 3	2,689	2012-04-06	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00649389	Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension	Phase 3	2,500	2010-09-01	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00902304	Valsartan Intensified Primary Care Reduction of Blood Pressure Study	Phase 4	2,337	2012-08-30	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00434967	Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo	Phase 3	2,207	2009-06-17	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00902538	Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension	Phase 3	2,204	2011-11-22	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00546052	A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)	Phase 3	1,738	2009-06-23	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00246519	Pharmacogenomic Evaluation of Antihypertensive Responses	Phase 4	1,701	2013-07-10	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00765674	Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension	Phase 3	1,191	2011-05-09	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT01033071	Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.	Phase 3	1,071	2012-02-07	hydrochlorothiazide	Its name	ClinicalTrials.gov
NCT00430950	Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension	Phase 3	1,011	2009-04-20	hydrochlorothiazide	Its name	ClinicalTrials.gov

1 to 10 of 387

See all 387 trials

Comparisons in its trials85

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dihydropyridine calcium channel blocker vs Hydrochlorothiazide: deaths from any cause	0 of 64,254	0 of 64,254	128,508	NCT05125224	Trial comparisons
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo vs OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo: Number of Participants Achieving Blood Pressure Goal.	260 of 502	255 of 508	1,010	NCT00430950	Trial comparisons
Losartan-Based Regimen Alone (L Group) vs Diet Management and Losartan-Based Regimen (DML Group): serious adverse events	13 of 531	10 of 453	984	NCT00739674	Trial comparisons
Telmisartan 40/80 mg vs Telmisartan 40/80 mg + HCTZ 12.5/25 mg: serious adverse events	1 of 294	0 of 594	888	NCT00926289	Trial comparisons
Aliskiren/HCTZ vs Amlodipine: serious adverse events	3 of 428	4 of 431	859	NCT00787605	Trial comparisons
Telmisartan 40/80 mg vs Telmisartan 40/80 mg + HCTZ 12.5/25 mg: Number of Patients With DBP Control (DBP < 90 mmHg) at Week 7	150 of 285	389 of 573	858	NCT00926289	Trial comparisons
Telmisartan 40/80 mg vs Telmisartan 40/80 mg + HCTZ 12.5/25 mg: Number of Participants With DBP Response at Week 7	202 of 285	483 of 573	858	NCT00926289	Trial comparisons
Telmisartan 40/80 mg vs Telmisartan 40/80 mg + HCTZ 12.5/25 mg: Number of Patients With Systolic Blood Pressure (SBP) Response at Week 7	233 of 285	527 of 573	858	NCT00926289	Trial comparisons
Telmisartan 40/80 mg vs Telmisartan 40/80 mg + HCTZ 12.5/25 mg: Number of Patients With SBP Control (SBP < 140 mmHg) at Week 7	122 of 285	363 of 573	858	NCT00926289	Trial comparisons
Telmisartan 40/80 mg vs Telmisartan 40/80 mg + HCTZ 12.5/25 mg: Number of Patients With BP Control at Week 7	99 of 285	318 of 573	858	NCT00926289	Trial comparisons

1 to 10 of 85

See all 85 comparisons in its trials

Papers from its trials295

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37702559	RESULT	1	PubMed
37176563	RESULT	1	PubMed
37105517	RESULT	1	PubMed
36856614	RESULT	1	PubMed
27819386	RESULT	1	PubMed
27819381	RESULT	1	PubMed
27298661	RESULT	1	PubMed
27041480	RESULT	1	PubMed
27040132	RESULT	1	PubMed
27039945	RESULT	1	PubMed

1 to 10 of 295

See all 295 papers from its trials

Tests in its trials3

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Digit Span Test	1	1	ConductCognition
Trail Making Test B	1	1	ConductCognition
Verbal Learning	1	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL435

GET https://conductscience.org/api/drugs/v1/CHEMBL435/diseases?page=2

API reference For AI assistants